BIIB
Biogen Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Biogen has 13 disclosed suppliers and 6 disclosed customers in SEC filings.
Last report2 of 5 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−3.43%
vs ±4.7% implied · ×0.74
shaded = implied · ▲▼ = realized
Biogen Inc.
253.65
+0.03 · +0.01%
post 248.97 −1.85%
SentenceFor a discussion of our agreements with Biogen related to VUMERITY, including the manufacturing and royalty revenue provisions set forth therein, see the section entitled " Collaborative Arrangements—Biogen " in "Item 1—Business" in this Annual Report.
SentenceWe currently fund our operations primarily with the proceeds from our follow-on offering completed in October 2022, payments received from our collaboration agreements with Biogen , Sanofi, Takeda, and a strategic private offering transaction completed in February 2024.
SentenceWe have funded our operations to date primarily from proceeds received under collaboration and license agreements with Sanofi, Lilly and Biogen
SCTX S-1/Aaccession 0001193125-26-308330SCTX
SentenceOn February 14, 2025, we entered into a License and Collaboration Agreement (the "Biogen Agreement") with Biogen International GmbH ("Biogen") for the joint development and commercialization of zorevunersen and other compounds targeting the SCN1A gene (the "Licensed Product").
SentenceWhile Biogen is obligated to reimburse us for the costs of supply related to marketing and sales in the Biogen Territory, we are required to fund the initial cash payments to third-party contract manufacturing organizations prior to receiving reimbursement from Biogen.
SentenceIn May 2025 we entered into a strategic research arrangement with City Therapeutics to develop select novel RNAi therapies.
BIIB 10-Kaccession 0000875045-26-000013
SentenceIn October 2025 we entered into a research collaboration with Dayra to discover and develop oral macrocyclic peptides for priority targets in immunological conditions.
BIIB 10-Kaccession 0000875045-26-000013
SentenceIn connection with the initiation of this dosing we paid a $30.0 million milestone payment to MorphoSys in July 2025.
BIIB 10-Kaccession 0000875045-26-000013
SentenceSamsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, which became effective as of January 2026.
BIIB 10-Kaccession 0000875045-26-000013
SentenceIn October 2025 we entered into a license agreement with Vanqua granting us exclusive worldwide rights to further develop, manufacture and commercialize Vanqua's preclinical oral C5aR1 antagonist compound.
BIIB 10-Kaccession 0000875045-26-000013
SentenceLRRK2 Program Manufacturing Biogen will be responsible for delivering all supplies for clinical trials and commercial production for LRRK2 Products, except that we will deliver such supplies until the point of transition which will be mutually agreed by us and Biogen, but in no event later than commencement of activities to support commercial launch, and in any event we retain manufacturing rights for certain independent clinical activities.
In September 2016, the Company entered into an asset purchase agreement (the "Biogen Agreement") with Biogen MA Inc. ("Biogen") to acquire all of Biogen's right, title and interest in and to certain assets used in or relating to vixarelimab and other antibodies covered by certain patent rights, including patents and other intellectual property rights, clinical data, know-how, and clinical drug supply.
SentenceOn September 8, 2023, we entered into a non-exclusive, sublicensable, worldwide, perpetual license agreement, or the Biogen Agreement, with Biogen MA, Inc., or Biogen, to research, develop, make, use, offer, sell and import products or processes containing or using an engineering T-cell modified with an mRNA comprising, or encoding a protein comprising, certain sequences licensed under the Biogen Agreement for the prevention, treatment, palliation and management of autoimmune diseases and disorders, excluding cancers, neoplastic disorders, and paraneoplastic disorders.
SentenceWe also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Supernus on the commercialization of ZURZUVAE for the treatment of PPD.
BIIB 10-Kaccession 0000875045-26-000013
Linked news
Expected move
No implied move.